Novo Nordisk and Hims & Hers end lawsuit, agreeing to sell Wegovy via Hims’ telehealth platform.

Novo Nordisk and Hims & Hers Health have settled their legal dispute over weight-loss drugs, with Novo agreeing to sell its medications, including Wegovy, through Hims’ telehealth platform. The deal ends a February 2026 lawsuit filed by Novo over Hims’ marketing of a compounded version of Wegovy, which it claimed infringed patents and raised FDA concerns. The partnership, expected to be announced soon, marks a shift from conflict to collaboration, expanding access to FDA-approved weight-loss treatments through a major direct-to-consumer health provider.